PYFA Sets Record Net Sales of IDR 2.76 Trillion in Fiscal Year 2025, EBITDA Reaches IDR 203.7 Billion
JAKARTA, 7 April 2026 – PT Pyridam Farma Tbk (IDX: PYFA) recorded accelerated growth in the 2025 fiscal year with net sales reaching IDR 2.76 trillion, a 43.7% year-on-year increase from IDR 1.92 trillion in 2024. Citing the consolidated financial statements for the 2025 fiscal year, the Company also began to show improvements at the operational level with an EBITDA of IDR 203.7 billion and a gross profit of IDR 583 billion. This reflects an increase in business scale as well as contributions from business lines with better margins.
PYFA’s net sales growth in 2025 was driven by strong expansion in the Contract Development and Manufacturing Organization (CDMO) line, which is increasingly becoming one of the Company’s strategic pillars. Continuously rising demand from both domestic and global pharmaceutical companies strengthens PYFA’s position as a trusted and integrated manufacturing partner amidst the toll manufacturing trend in the pharmaceutical industry.
Over the past 5 years, PYFA has consistently expanded its production capacity and strengthened its manufacturing infrastructure. This capacity increase is crucial for capturing opportunities from the continuously growing CDMO market, in line with the increasing need for efficiency and specialization in the global pharmaceutical industry. Several innovative products supporting this growth include Cytoflavin, Reamberin, Syalox, and the sterile injection line.
“The year 2025 was a challenging year, but our achievements prove the fundamental resilience of PYFA in navigating difficult market dynamics. Entering the next phase, the Company’s main focus shifts to optimizing profitability. We will implement much stricter and more measured operational efficiency measures across all business lines, ensuring the company operates in a leaner and more disciplined manner to sustain healthy long-term growth,” said Sinta Ningsih, Director of PYFA.
Amidst this growth, the Company still recorded a net loss, which was impacted by high operational expenses and ongoing strategic investments. The Company stated that this phase is part of its effort to build long-term capabilities and expand PYFA’s position within the broader healthcare ecosystem.
One of the strategic investments made by the Company in 2025 was the consolidation of the Probiotec facility in Kemps Creek, New South Wales, Australia, and the construction of the Line 3 facility in Cikarang, which was completed at the end of the year. The Kemps Creek facility was fully operational by the end of 2025, while the Line 3 facility in Cikarang, which has double the production capacity of Line 2, is ready to commence commercial activities in 2026.
Furthermore, the Company’s growth strategy in 2026 will focus on three main pillars: the expansion of sterile production facilities in Cikarang (Lines 4 and 5), the strengthening of CDMO services, and a focus on a high-value, licensed therapeutic product portfolio. This step is also supported by selective corporate actions that establish PYFA as a company with a comprehensive end-to-end healthcare ecosystem.
With a combination of manufacturing capabilities, access to global partnerships, and a measured expansion strategy, the Company sees an opportunity to take a more significant role in the healthcare industry value chain, both in domestic and international markets.
About PYFA
PT Pyridam Farma Tbk, known under the brand PYFA, is a public pharmaceutical company listed on the Indonesia Stock Exchange (Ticker: PYFA). PYFA operates several business units producing prescription medicines in various forms, including tablets, capsules, creams, and injections. PYFA also has several well-known subsidiaries, including PT Holi Pharma, PT Ethica Industri Farmasi, and Probiotec Multipack.
Media Relations
Leilanie Nadia Kusuma
Head of Corporate Communications
Website : www.pyfa.co.id
Email : corcomm@pyfa.co.id
